Discover 3,097 paid clinical trials in Worcester, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,097
Telerehabilitation In The Home After Stroke
for
Stroke
Location: Boston MA, Charlestown MA, Springfield MA, New York NY,
Sponsor: University of California, Los Angeles
Sex: All
Age: 18 - 70+
Code: NCT06682429
Recruiting
Semaglutide for Helping Opioid Recovery
for
Opioid Use Disorder
Location: Boston MA
Sponsor: Brigham and Women's Hospital
Sex: All
Age: 18+
Code: NCT06639464
Phase2, Recruiting
Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility
Effects of Aphasia Identification Cards on Service Workers' Comprehension of People With Aphasia
for
Aphasia
Location: Springfield MA
Sponsor: University of Massachusetts, Amherst
Sex: All
Age: 18 - 59
Code: NCT06990997
Recruiting
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
for
Metastatic Breast Cancer, HER2 Low Breast Carcinoma,
Location: Boston MA
Sponsor: Kristina A. Fanucci
Sex: All
Age: 18+
Code: NCT07198724
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
for
Ovarian Cancer, Fallopian Tube Cancer,
Location: Boston MA, Greenfield Park, Montreal, Quebec, Toronto,
Sponsor: Regeneron Pharmaceuticals
Sex: Female
Age: 18+
Code: NCT06787612
Phase2, Recruiting
Treating Insomnia in Mild Cognitive Impairment
for
Mild Cognitive Impairment (MCI), Insomnia
Location: Boston MA
Sponsor: Beth Israel Deaconess Medical Center
Sex: All
Age: 60+
Code: NCT06687161
Recruiting
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation